Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-23T16:52:00.857Z Has data issue: false hasContentIssue false

Preclinical immunological testing of engineered nanoparticles: regulatory and methodological challenges

Published online by Cambridge University Press:  12 July 2019

Marina A. Dobrovolskaia
Affiliation:
SAIC-Frederick Inc
Scott E. McNeil
Affiliation:
SAIC-Frederick Inc
Get access

Abstract

Format

This is a copy of the slides presented at the meeting but not formally written up for the volume.

Abstract

The potential applications of nanomaterials in medicine are numerous and very promising. Translation of potential to practical value, however, requires demonstration not only of efficacy but also of safety. Assessing nanoparticles? potential toxicity to the immune system is an important step in building nanopartricles? safety profile. Unfortunately, immunotoxicological analysis of new molecular entities is not a straightforward process. There is no universal guide for immunotoxicity in general, as there is no formal guide specific for nanomaterials?. Our presentation will address key points for consideration during early preclinical studies on nanoparticles? effects to the immune system. We will also review methodological challenges in in vitro preclinical immunological testing of nanomaterials developed for biological applications. Funded by NCI Contract N01-CO-12400.

Type
Slide Presentations
Copyright
Copyright © Materials Research Society 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)